Targeting non-alcoholic fatty liver disease: Design, X-ray co-crystal structure and synthesis of ‘first-in-kind’ inhibitors of serine/threonine kinase25-Reference-Cited by-同舟云学术

Targeting non-alcoholic fatty liver disease: Design, X-ray co-crystal structure and synthesis of ‘first-in-kind’ inhibitors of serine/threonine kinase25

Published:2022-11 Issue: Volume:75 Page:128950
ISSN:0960-894X
Container-title:Bioorganic & Medicinal Chemistry Letters
language:en
Short-container-title:Bioorganic & Medicinal Chemistry Letters

Author:

Kiyeleko Scarlett,Hocine Sofiane^ORCID,Mautino Giséle,Kuenemann Mélaine,Nawrotek Agata,Miallau Linda,Vuillard Laurent-Michel,Mirguet Olivier^ORCID,Kotschy Andras^ORCID,Hanessian Stephen

Funder

Servier

Natural Sciences and Engineering Research Council of Canada

Publisher

Elsevier BV

Subject

Organic Chemistry,Clinical Biochemistry,Drug Discovery,Pharmaceutical Science,Molecular Biology,Molecular Medicine,Biochemistry

Reference54 articles.

1. The Global NAFLD Epidemic;Loomba;Nat Rev Gastroenterol Hepatol,2013

2. Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention;Younossi;Nat Rev Gastroenterol Hepatol,2017

3. Non-alcoholic fatty liver disease (NAFLD)/non-alcoholic steatohepatitis (nash)-related liver fibrosis: mechanisms, Treatment and Prevention;Tacke;Ann Transl Med,2021

4. NAFLD, NASH and Liver Cancer;Michelotti;Nat Rev Gastroenterol Hepatol,2013

5. Mullard, A. FDA Rejects NASH Drug. Nature reviews. Drug discovery. NLM (Medline) August 1, 2020, p 501. https://doi.org/10.1038/d41573-020-00126-9.

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Chemoselective Reactions of Functionalized Sulfonyl Halides;The Chemical Record;2023-10-12

2. STK25: a viable therapeutic target for cancer treatments?;Anti-Cancer Drugs;2023-10

3. STK25 is an IRF5 kinase that promotes TLR7/8-mediated inflammation;2023-09-26